4-(甲氧基甲甲基)-3-硝基吡啶 | 784173-88-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 4-(甲氧基甲甲基)-3-硝基吡啶
• 英文名称: 4-(methoxycarbomethyl)-3-nitropyridine
• 英文别名: methyl 2-(3-nitropyridin-4-yl)acetate；methyl 2-(3-nitro-4-pyridyl)acetate
• CAS: 784173-88-2
• 化学式: C₈H₈N₂O₄
• 分子量: 196.163
• InChiKey: CQBDWWXDFBHXRE-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38 °C
• 沸点：
  305.5±27.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(甲氧基甲甲基)-3-硝基吡啶 在 potassium tert-butylate 、 苄基三乙基氯化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 7.0h， 生成 methyl 1-(3-nitro-4-pyridyl)cyclopropanecarboxylate
  参考文献：
  名称：

  [EN] NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
  [FR] NOUVEAUX AZA-OXO-INDOLES POUR LE TRAITEMENT ET LA PROPHYLAXIE DE L'INFECTION PAR LE VIRUS RESPIRATOIRE SYNCYTIAL

  摘要：

  这项发明提供了具有通式(I)的新化合物，其中R1、R2、R3、R4、W和X如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。

  公开号：

  WO2015022263A1
• 作为产物：
  描述：

  4-氯-3-硝基吡啶 在 sodium hydride 、 lithium chloride 作用下， 以 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 8.5h， 生成 4-(甲氧基甲甲基)-3-硝基吡啶
  参考文献：
  名称：

  [EN] NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
  [FR] NOUVEAUX AZA-OXO-INDOLES POUR LE TRAITEMENT ET LA PROPHYLAXIE DE L'INFECTION PAR LE VIRUS RESPIRATOIRE SYNCYTIAL

  摘要：

  该发明提供了具有以下一般式的新化合物：其中R1、R2、R3、R4、R5、W和X如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。

  公开号：

  WO2015022301A1

文献信息

• [EN] NEW ENZYME INHIBITOR COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS ENZYMATIQUES
  申请人：PROXIMAGEN LTD

  公开号：WO2013037411A1

  公开（公告）日：2013-03-21

  2-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3- aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4- (dimethylamino)butan-1-one; 5-amino-1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3- yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H- pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1- [1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4- methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4- chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2- aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4 yl}carbonyl)morpholine; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin- 4-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin- 3-yl}methanol; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3- yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3- carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]morpholine-3-carboxamide; 2-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4- c]pyridin-3-yl]piperidine-2-carboxamide; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4- c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4- ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4- (fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-(4-[1-(4- chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.

  2- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}乙基-1-胺; 3-氨基丙基4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酸酯; 1- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}-4- (二甲基氨基)丁酮; 5-氨基-1- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3- 基]哌啶-1-基}戊酮; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; N- (3-氨基丙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; 4- [1- (4-氯苯基)-1H-吡咯并[2,3- c]吡啶-3-基]-N- [3- (二甲基氨基)丙基]哌啶-1-羧酰胺; 1- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)哌嗪; 4- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)吗啉; 1- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)-1,4-二氮杂辛烷; 乙基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 乙基1- [1- (4- 甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 1- [1- (4- 氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酰胺; 4- (1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4- 基}羰基)吗啉; 1- (1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶- 4-基}羰基)哌嗪; 4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉- 3-基}甲醇; 4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-2-基}甲醇; [(3R)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3- 基]甲醇; 甲基4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酸酯; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-羧酰胺; 2- 4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-基}乙基-1-醇; 甲基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]哌啶-2-羧酸酯; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-羧酰胺; 1- (1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-基}羰基)哌嗪; 4- [1- (4-甲基苯基)-1H-吡咯并[2,3- c]吡啶-3-基]吗啉; 1- (4-氯苯基)-3- (哌啶-4-基)-1H-吡咯并[2,3-c]吡啶-4- 醇; N-丁基-1- (4-氯苯基)-N-甲基-1H-吡唑并[3,4-c]吡啶-3-胺; 1- [4- (氟甲基)苯基]-3- (氧杂环丁基)-1H-吡咯并[3,4-c]吡啶; 和3- (4- [1- (4- 氯苯基)-1H-吡咯并[3,4-c]吡啶-3-基]哌啶-1-基}甲基)吡啶对于抑制SSAO活性是有用的。
• Nucleophilic alkylations of 3-nitropyridines
  作者：Einar J. Andreassen、Jan M. Bakke、Ingrid Sletvold、Harald Svensen

  DOI：10.1039/b408840a

  日期：——

  3-Nitropyridine and 4-substituted-3-nitropyridines were reacted with chloroform, methyl chloroacetate and ethyl 2-chloropropionate under vicarious nucleophilic substitution (VNS) conditions. Substitution was obtained in the ortho or para position to the nitro group with acceptable to good yields and regioselectivity. With potassium 5-nitropyridine-2-sulfonate the substitution took place in the 4-position. Further substitution of the sulfonate group proved to be possible.

  3-硝基吡啶和4-取代-3-硝基吡啶在代换亲核取代（VNS）条件下与氯仿、氯甲酸甲酯和氯丙酸乙酯反应。取代发生在硝基组的邻位或对位，产率和区域选择性均达到可接受到良好的水平。使用5-硝基吡啶-2-磺酸钾时，取代发生在4位。进一步对磺酸根的取代也被证明是可行的。
• Preparation of 6-azaoxindole (6-azaindol-2(3<i>H</i>)-one) and substituted derivatives
  作者：Einar J. Andreassen、Jan M. Bakke

  DOI：10.1002/jhet.5570430107

  日期：2006.1

  A general synthesis of 6-azaoxindoles, substituted in the 3- and 5-position, has been developed starting from 4-methoxycarbomethyl-3-nitropyridine, via hydrogenation of the nitro group and cyclisation of the resulting 3-amino-4-methoxycarbomethyl-pyridine.

  由4-甲氧基碳甲基-3-硝基吡啶开始，通过硝基的氢化和环化所得的3-氨基-4-甲氧基碳甲基-，已经开发了在3-和5-位被取代的6-氮杂肟基的一般合成。吡啶。
• NEW ENZYME INHIBITOR COMPOUNDS
  申请人：Evans David

  公开号：US20140357623A1

  公开（公告）日：2014-12-04

  2-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4 yl}carbonyl)morpholine; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol; 4-[1-(4-methyl-phenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide; 2-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-(4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.

  2-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}乙基-1-胺; 3-氨基丙基 4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酸酯; 1-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}-4-(二甲基氨基)丁酮; 5-氨基-1-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}戊酮; N-(2-氨基乙基)-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; N-(3-氨基丙基)-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; 4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]-N-[3-(二甲胺基)丙基]哌啶-1-羧酰胺; 1-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)哌嗪; 4-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)吗啉; 1-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)-1,4-二氮杂环庚烷; 乙酸乙酯 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 乙酸乙酯 1-[1-(4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸; N-(2-氨基乙基)-1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酰胺; 4-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-基}羰基)吗啉; 1-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-基}羰基)哌嗪; 4-[1-(4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基}甲醇; 4-[1-(4-甲基-苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-2-基}甲醇; [(3R)-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基]甲醇; 甲酸甲酯 4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酸酯; N-(2-氨基乙基)-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酰胺; 2-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基}乙基-1-醇; 甲酸甲酯 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-羧酸酯; N-(2-氨基乙基)-1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-羧酰胺; 1-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-基}羰基)哌嗪; 4-[1-(4-甲基苯基)-1H-吡咯并[2,3-c]吡啶-3-基]吗啉; 1-(4-氯苯基)-3-(哌啶-4-基)-1H-吡咯并[2,3-c]吡啶-4-醇; N-丁基-1-(4-氯苯基)-N-甲基-1H-吡唑并[3,4-c]吡啶-3-胺; 1-[4-(氟甲基)苯基]-3-(氧杂环丁基)-1H-吡唑并[3,4-c]吡啶; 和3-(4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-1-基}甲基)吡啶可用于抑制SSAO活性。
• PHARMACEUTICAL COMPOUNDS
  申请人：re:Viral Ltd

  公开号：US20140308282A1

  公开（公告）日：2014-10-16

  Benzimidazoles of formula (I): wherein: A is 5- to 12-membered aryl or 5- to 12-membered heteroaryl, each of which is unsubstituted or substituted; Y is a single bond, —(CH 2 ) p —, —X—, —CH 2 —X—, or —X—CH 2 —; X is —O—, —S—, —N(R 2 )—, >C═O, >S(═O), >S(═O) 2 , —O—C(═O)—, —C(═O)—O—, N(R 2 )—C(═O)—, or —C(═O)—N(R 2 )—; each L is independently a single bond, C 1-3 alkylene, C 2-3 alkenylene or C 2-3 alkynylene; R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is unsubstituted or substituted; each Z is independently —N(R 2 ) 2 , —OR 2 , —SR 2 , —S(═O)R 2 , —S(═O) 2 R 2 ; each R 2 is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein said alkyl, alkenyl and alkynyl groups are unsubstituted or substituted; m is 0, 1, 2, or 3; n is 1, 2, or 3; and p is 1, 2, or 3; and the pharmaceutically acceptable salt thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

  式(I)中的苯并咪唑：其中：A是5-至12-成员芳基或5-至12-成员杂芳基，每个都未取代或取代；Y是单键，—(CH2)p—，—X—，—CH2—X—或—X—CH2—；X是—O—，—S—，—N(R2)—，>C═O，>S(═O)，>S(═O)2，—O—C(═O)—，—C(═O)—O—，N(R2)—C(═O)—或—C(═O)—N(R2)—；每个L独立地是单键，C1-3烷基，C2-3烯烃基或C2-3炔烃基；R1是C1-6烷基，C2-6烯基或C2-6炔基，每个都未取代或取代；每个Z独立地是—N(R2)2，—OR2，—SR2，—S(═O)R2，—S(═O)2R2；每个R2独立地是氢，C1-6烷基，C2-6烯基或C2-6炔基，其中所述烷基，烯基和炔基基团未取代或取代；m为0、1、2或3；n为1、2或3；p为1、2或3；及其药用盐是RSV的抑制剂，因此可用于治疗或预防RSV感染。

表征谱图